Medically reviewed on June 18, 2018.
Applies to the following strengths: 6.25 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Mucositis
60 mcg/kg IV (as a bolus) once a day, administered for 3 consecutive days before and 3 consecutive days after myelotoxic therapy
-Prior to myelotoxic therapy: The third dose should be administered 24 to 48 hours prior to beginning the myelotoxic agent.
-Following myelotoxic therapy: The first dose should be administered on the day of hematopoietic stem cell infusion after the infusion is complete, AND at least 7 days after the most recent dose of this drug.
-Decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support
-Supportive care for preparative regiments predicted to result in greater than or equal to WHO Grade 3 mucositis in the majority of patients
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Data not available
Safety and efficacy have not been established in patients younger than 1 year.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be given as a IV bolus injection; the solution should not be filtered.
-If heparin is used, IV lines should be rinsed with saline prior to and after administration.
-Prior to administration, this drug should be allowed to reach room temperature for up to 1 hour (protected from light); however, this drug will need to be discarded in excursions exceeding 1 hour.
-Unopened vials: Store refrigerated (2 to 8C), and protect from light. Do not freeze.
-Reconstituted solution: The solution may be stored refrigerated (2 to 8C) and protected from light in its carton for up to 24 hours; the solution should be discarded after 24 hours if it is not used.
-Reconstituted solutions left at room temperature for longer than 1 hour should be discarded.
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
-Compatible: Sterile water for injection
-Other medications should not be added to solutions containing this drug.
-Safety and efficacy have not been established in patients with non-hematologic malignancies.
-This drug was not effective in decreasing severe mucositis in patients with hematologic malignancies who were receiving myelotoxic therapy with allogenic hematopoietic stem cell support.
-Once reconstituted, it is recommended that this drug is used immediately.
-Limitation of use: Treatment is not recommended for use with melphalan 200 mg/m2 as a conditioning regimen.
-HEMATOLOGIC: Platelet counts
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
More about palifermin
- Palifermin Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: miscellaneous uncategorized agents
Other brands: Kepivance